Try GOLD - Free
A dose of AI
Business Standard
|July 02, 2025
From detecting cancer to reshaping diagnosis and treatment, artificial intelligence is changing the DNA of health care with the promise of a 'healthier human'. The second of a three-part series
In early 2024, Marly Garnreiter, a 27-year-old French woman, began experiencing persistent night sweats and itchy skin. Her doctors dismissed it as stress. Her blood report came back normal. Out of curiosity, she asked ChatGPT about it. The artificial intelligence (AI) chatbot suggested she might have blood cancer. Nearly a year later, in April 2025, doctors confirmed she had Hodgkin's lymphoma, a cancer that affects the lymphatic system.
Stories like Garnreiter's are making headlines repeatedly: AI catching what humans miss.
While anecdotal, they point to a shift underway in health care—one where AI doesn't replace doctors but sharpens their eyes and expands their reach. And also, frees up the time doctors and nurses spend on tasks like writing patient summaries, current patient condition, treatment plan, and so on.
Discharge summaries and reports, too, are being prepared by AI and sent to patients, after a human has crosschecked them for errors.
"The future lies in human-AI collaboration, where technology enhances our diagnostic and therapeutic capabilities," says Bharat Aggarwal, principal director, radiology services, Max Super Speciality Hospital, Saket, Delhi. The hospital chain is implementing AI in 'shadow mode', running predictions alongside human clinicians to verify accuracy before actual deployment.
"AI is reshaping the healthcare landscape at a brisk pace," says Venkatesh Krishnan, executive director, public sector, health care, education, Microsoft India and South Asia. "Globally, 79 per cent of health care and lifesciences companies are leveraging AI to drive better outcomes." In India, he says, this momentum is visible as healthcare systems navigate workforce challenges, rising patient expectations, and need for personalized care.
This story is from the July 02, 2025 edition of Business Standard.
Subscribe to Magzter GOLD to access thousands of curated premium stories, and 10,000+ magazines and newspapers.
Already a subscriber? Sign In
MORE STORIES FROM Business Standard
Business Standard
Labour Codes impact: HCL tech profit slips 11%
Q3 top line beats Street estimates, bottom line misses expectations
2 mins
January 13, 2026
Business Standard
New labour Codes, restructuring weigh on TCS earnings
Tata Consultancy Services (TCS), India’s largest information technology (IT) services firm, saw its profit impacted in the October-December quarter by restructuring and changes in labour Codes.
1 min
January 13, 2026
Business Standard
Black drives the thrill for car buyers
Sees a surge in yearly sales, while white remains practical 'utility king'
2 mins
January 13, 2026
Business Standard
CHOOSING THE RIGHT B-SCHOOL TO MATCH YOUR CAREER GOALS
Success comes when you pick an institution that fits your professional dreams and your personality, helping you become the leader you want to be
2 mins
January 13, 2026
Business Standard
China’s PVC rethink to help India pipe makers
Supply likely to tighten after S-PVC rebate withdrawal
2 mins
January 13, 2026
Business Standard
Responsible growth
India must ensure data centres are sustainable
2 mins
January 13, 2026
Business Standard
India’s GenZ is full of creativity: PM
Prime Minister Narendra Modi on Monday said India's GenZ is full of creativity and with innovative ideas, energy and purpose, the country’s youth is at the forefront of nation-building.
1 min
January 13, 2026
Business Standard
Iran wants to negotiate after threats to attack, says Trump
At least 572 killed in protests; Tehran says situation ‘under full control’
2 mins
January 13, 2026
Business Standard
Insurers knock on Irdai door for clarity on director overlap ban
CLAUSE THREATENS BOARD STRUCTURES AT BANK-BACKED FIRMS SAYS INDUSTRY
2 mins
January 13, 2026
Business Standard
Delhi HC allows Zydus to sell generic version of cancer drug
Citing public interest, the Delhi High Court has cleared the way for Zydus Life-sciences to proceed with the sale of its version of the cancer drug nivolumab in India.
1 min
January 13, 2026
Listen
Translate
Change font size
